Abstract:Cutaneous and Oral Squamous Cell Carcinoma (SCC) is the second most common skin and most common mucosal cancers, respectively. A subset of head and neck SCC are at high-risk of local recurrence or developing metastases. The prognosis of patients with metastatic and recurrent HNSCC is poor, with a median survival rate of less than 12-months in many instances. The immune system plays a critical role in the control of many malignancies including SCC. Recent clinical trials with immune checkpoint inhibitors (ICI) demonstrate response in 47% of patients with advanced cutaneous SCC (cSCC) but only 19% in patients with advanced oral SCC (oSCC). In this study we used high-dimensional imaging mass cytometry to examine up to 40 parameters to compare the tumor microenvironment of cSCC and oSCC. In cSCC we discovered that patient tumors contained immune signatures and individual cell interactions that link progression to immune status in patients absent of clinical immune suppression (ACIS). There were significant differences in the CD4+, CD8+ T cell and leukocyte immune composition of primary tumors that never progressed compared to primary tumors from DP patients ACIS. We also found significant spatial differences in primary tumors from these patients including cell-interactions and specific regions present in the TME landscape. Cellular regional analysis of the TME showed squamous cell-enriched tumor regions associated with DP tumors. In oSCC, patients who did not respond to ICI showed significantly higher infiltrates of proliferating CD4+ Regulatory T cells (Tregs). NK cells and Central Memory Cytotoxic T cells were found to be significantly higher in patients who responded to therapy. Furthermore, we identified key spatial interactions including a subset of Tregs significantly interacting with specific PMN-myeloid derived suppressor cells (MDSC) in patients who failed to respond to PD-1 ICI. Interestingly, these Tregs and PMN-MDSCs were found to significantly avoid each other in the TME of patients who responded to PD-1 ICI. Mapping the immune landscape of human tumors could provide insight into the role of immune cells in disease progression and response and resistance to therapy. The findings of this research offers a clear pathway to determine clinical outcomes based on a patients TME signature. Citation Format: Angela L. Ferguson, Thomas Beddow, Ashleigh Sharman, Ruth O. Allen, Thomas Ye, Jenny Lee, Tsu-Hui (Hubert) Low, Sydney Ch'ng, Carsten Palme, Bruce Ashford, Marie Ranson, Michael Elliot, Jonathan R. Clark, Ellis Patrick, Umaimainthan Palendira, Ruta Gupta. High-dimensional spatial analysis of the tumor-microenvironment to determine metastatic disease progression and response and resistance to therapy in head and neck cancer [abstract]. In: Proceedings of the AACR-AHNS Head and Neck Cancer Conference: Innovating through Basic, Clinical, and Translational Research; 2023 Jul 7-8; Montreal, QC, Canada. Philadelphia (PA): AACR; Clin Cancer Res 2023;29(18_Suppl) nr PR12.

Correlation Of T-Cell Inflamed Phenotype With Mesenchymal Subtype, Expression Of Pd-L1, And Other Immune Checkpoints In Head And Neck Cancer

Correlation of Specific Genetic Aberrations and Signaling Pathways with T-cell Inflamed Phenotype (TCIP) in Head and Neck Cancer and As Novel Candidate Biomarkers for Checkpoint Blockade Therapy.

Patterns of Cd8+T-Cell Infiltration and Immune Escape Mechanisms in Head and Neck Cancer

Identification of lncRNA Signature of Tumor-Infiltrating T Lymphocytes With Potential Implications for Prognosis and Chemotherapy of Head and Neck Squamous Cell Carcinoma

Exploratory Analysis of Clinical and Translational Factors Associated with the Inflamed Phenotype in Hnscc.

Correlation of Constitutive PD-1 Resistance in HNC with GM-CSF Expression and Presence of Myeloid Derived Suppressor Cells (Mdscs).

Immune Profiles in Primary Squamous Cell Carcinoma of the Head and Neck.

Noncanonical HPV carcinogenesis drives radiosensitization of head and neck tumors

Correlation of Intra-tumoral and Peripheral PD-1/PD-L1 Immunity in Head and Neck Cancer

Compartmentalized spatial profiling of the tumor microenvironment in head and neck squamous cell carcinoma identifies immune checkpoint molecules and tumor necrosis factor receptor superfamily members as biomarkers of response to immunotherapy

Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy

Type I conventional dendritic cells and CD8+ T cells predict favorable clinical outcome of head and neck squamous cell carcinoma patients

Expression of PD-L1, PD-L2, and inflammatory gene expression profile in locally advanced head and neck squamous cell carcinoma

Immune Cell Abundance and T-cell Receptor Landscapes Suggest New Patient Stratification Strategies in Head and Neck Squamous Cell Carcinoma

Impact of T Cell Exhaustion and Stroma Senescence on Tumor Cell Biology and Clinical Outcome of Head and Neck Squamous Cell Carcinomas

Association of Driver Genes with High-Tumor Mutation Burden and Outcome in Patients with Head and Neck Cancer: Implications for Immunotherapy.

Bioinformatics Analysis for the Biomarkers of the Tumor-Infiltrating Lymphocytes in Head and Neck Squamous Cell Carcinoma.

The Microenvironment of Head and Neck Cancers: Papillomavirus Involvement and Potential Impact of Immunomodulatory Treatments

Biomarkers predictive of response to pembrolizumab in head and neck cancer

Interrogating the tumor microenvironment (TME) in patients (pts) with head and neck mucosal squamous cell carcinoma (HNmSCC) treated with programmed death-1 (PD-1) inhibitors.

Abstract PR12: High-dimensional spatial analysis of the tumor-microenvironment to determine metastatic disease progression and response and resistance to therapy in head and neck cancer